Zhejiang Tianyu Pharmaceutical Co., Ltd. (hereinafter referred to as "the Company") announces that its wholly-owned subsidiary, Zhejiang Tianyu Pharmaceutical Co., Ltd. (hereinafter referred to as "Tianyu Pharmaceutical"), has recently received approval from the National Medical Products Administration (hereinafter referred to as "NMPA") for the drug Trimebutine Maleate Tablets. The relevant information is as follows:
300702SZSE
🚨 Material Event
Announcement on the Approval of Subsidiary's Drug
✨ AI Summary
This announcement informs that the subsidiary of Zhejiang Tianyu Pharmaceutical Co., Ltd. has received approval for Trimebutine Maleate Tablets. The drug is classified as a chemical product and is expected to generate significant revenue. The approval is valid until June 2, 2031, with anticipated sales growth impacting the company's financial performance.
Summary generated by AI · Always verify with source document
Full Translation
AI Translation· azure_openai
Sign in to read the full translation
Free accounts get 10 full releases per month. Pro subscribers get unlimited access.